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3D QSARAbstract Context: In recent years phosphodiesterase V acts as an attractive target for cardiovas-
cular drug design and QSAR techniques are helpful for the optimization of structural requirements
for designing novel compounds.
Objective: The present communication deals with 3D-QSAR analysis of 1-(2-ethoxyethyl)-1H-
pyrazolo[4,3-d]pyrimidines as phosphodiesterase V inhibitors.
Materials and methods: The multiple linear regression analysis and kNN-MFA analysis were
carried out on 33 reported 1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines in Vlife MDS 3.5.
Results: The substitution of electron withdrawing groups in pyrazole ring and sterically less
bulkier groups is important for the phosphodiesterase V inhibition indicated by both QSAR anal-
yses.
Conclusion: The two different QSAR models are generated by using two different principles,
both the models are showing similar results which indicate that this kNN-MFA technique can be
utilized for cross validation of the results of multiple linear regression studies.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Phosphodiesterase enzymes catalyze the conversion of cyclic
GMP and cyclic AMP into the corresponding nucleotidemonophosphates with the emergence of molecules like sildena-
ﬁl and tadalaﬁl. The phosphodiesterase 5 (PDE5) inhibition is
now emerged as the most favorite tool for the treatment of
erectile dysfunction in men. Large amount of research is car-
ried out for the identiﬁcation of new, selective PDE5 inhibitors
and to investigate their usefulness in cardiovascular disorders
to act as vascular smooth muscle relaxants. In human PDE5
is frequently observed in lungs, platelets, and vascular smooth
muscles. PDE5 is speciﬁc for the cGMP, in its both catalytic
sites, and in the two cGMP-binding allosteric sites (Sausbier
et al., 2000; McAllister-Lucas et al., 1993; Chang et al., 2010;
Tollefson et al., 2010; Yang et al., 2006). In PDE5 there are
266 P. Choudhari, M. Bhatiatwo cGMP-binding domains: (i) an N-terminal domain har-
boring a site for phosphorylation and (ii) a C-terminal cata-
lytic domain of the enzyme (Chen et al., 2009, 2008;
Matsumoto et al., 2003; Reffelmann and Kloner, 2009; Guazzi,
2008; Palmer et al., 2007; Srivani et al., 2007; Rotella, 2002).
The catalytic domain of PDE5 is constituted by four major
parts which includes three helical subdomains, an N-terminal
cyclin-fold region, a linker region and a C-terminal helical
bundle. The present communication deals with 3D QSAR (Fe-
gade et al., 2009; Jhaa et al., 2009; Sharma and Sharma, 2010)
analysis of 1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines
derivatives by multiple linear regression and k-nearest neigh-
bor molecular ﬁeld analysis (kNN-MFA) for the designingTable 1 The molecules under study.
N
N
N
N
R1
O
HN
R2
Sr. no. R2 R1 3D QSAR by MLR
Obs. Act Pre. Act
1 Et 1.154902 0.976007
2
N
0.39794 0.335082
3
N
Et 1.154902 1.091625
4
N
Me 0.187087 0.427347
5
N
Et 0.180456 0.329883
6
N
Me 0.14613 0.42503
7
N
Et 0.420216 0.315386
8
N
Et 0.51851 0.630618
9
N
Et 0.74036 0.204248of new phosphodiesterase 5 inhibitors with vascular smooth
muscle relaxant activity.
2. Computational details
2.1. Dataset
A dataset of 33 compounds was taken from the published
phosphodiesterase V inhibitors by Tollefson et al. (2010).
The structures and their inhibitory activities are listed in Ta-
ble 1. The inhibitory activity IC50 values were converted into
the corresponding pIC50 (log1/IC50) and used as dependent
variables in the 3D-QSAR analyses. The whole dataset wasN
NH
3D QSAR by kNN-MFA
Res Obs. Act Pre. Act Res
0.178895 1.154902 1.23208 0.07718
0.062858 0.39794 0.463477 0.06554
0.063277 1.154902 1.22774 0.07284
0.24026 0.187087 0.564074 0.37699
0.14943 0.180456 -0.63399 0.814449
0.278901 0.14613 0.35629 0.210165
0.10483 0.420216 0.102351 0.317865
1.14913 0.51851 0.27698 0.24153
0.94461 0.74036 0.15243 0.58793
Table 1 (continued)
N
N
N
N
R1
O
HN
N
N
R3
R4
Sr. no. NR3R4 R1 3D QSAR by MLR 3D QSAR by KNN-MFA
Obs. Act Pre. Act Res Obs. Act Pre. Act Res
10 N
N
Me 0.41497 0.50069 0.085718 0.41497 0.34802 0.06696
11
N
N
Et 0.05061 0.043787 0.006823 0.05061 0.07732 0.127927
12
N
NH
Et 0.39794 0.12422 0.27373 0.39794 0.35668 0.04126
13
N
NH
Et 0.07918 0.03801 0.04117 0.07918 0.2384 0.159214
14
N
NH
Et 0.119186 0.098904 0.020282 0.119186 0.08439 0.203571
15
NH
N
H
Me 0.36173 0.27329 0.08844 0.36173 0.039018 0.40075
16
NH
N
H
Et 0.69897 0.87657 0.1776 0.69897 0.478146 0.220824
17
N
N
H
Et 0.142668 0.04478 0.187449 0.142668 0.206722 0.06405
18
N
N
H
Et 0.30103 0.26987 0.03116 0.30103 0.40652 0.105488
19
N
N
Et 1.060481 0.885741 0.17474 1.060481 0.1778 0.882681
20 NH Et 0.376751 0.61674 -0.23999 0.376751 0.220577 0.156174
21
N
NH2
Me 0.36173 0.45437 0.09264 0.36173 0.054078 0.41581
22
N
NH2
Et 0.107905 0.496674 0.38877 0.107905 0.41973 0.31183
23
NH
N
H Me 0.455932 0.496674 0.04074 0.455932 0.836395 0.38046
(continued on next page)
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Table 1 (continued)
Sr. no. NR3R4 R1 3D QSAR by MLR 3D QSAR by KNN-MFA
Obs. Act Pre. Act Res Obs. Act Pre. Act Res
24
NH
N
H
Et 1.958607 1.263955 0.694652 1.958607 1.65955 0.299057
25
N
NH2
Me 1.154902 0.942938 0.211964 1.154902 1.27769 0.12279
26
N
NH2
Et 2.154902 2.102652 0.05225 2.154902 1.55393 0.600972
27
O
N
H
Me 0.07918 0.011897 0.09108 0.07918 0.058994 0.13818
28 N
OH
Et 1.154902 1.066985 0.087917 1.154902 0.74195 0.412952
29*
N
NH2
O
Me 0.721246 0.824059 0.10281 0.721246 0.835285 0.11404
30*
N
NH2
O
Et 1.09691 0.756023 0.340887 1.09691 1.18131 0.0844
31* N NH2
O
Et 1.09691 0.756023 0.340887 1.09691 1.18131 0.0844
32*
N
OH
O
Me 1.30103 1.426039 0.12501 1.30103 1.1549 0.14613
33*
N
OH
O
Et 1.39794 0.771842 0.626098 1.39794 0.06902 1.466957
* Test set molecules.
268 P. Choudhari, M. Bhatiarandomly divided into a training set of 28 compounds and a
test set of 5 compounds (asterisked molecules in Table 1).
The training set was used to construct the 3D-QSAR models
and the test set was used for the models validation.
2.2. Materials and methods
2.2.1. Ligand preparation
The structure of substituted derivatives was used as the tem-
plate to 1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines built
molecules in the dataset in Vlife MDS 3.5. All the structures
were minimized using the standard Merck molecular force ﬁeld
(MMFF) with the distance dependant dielectric function and
an energy gradient of 0.001 kcal/mol A˚.2.2.2. Molecular alignment
The molecules of the dataset were aligned by the template
based technique, using the common structure of 1-(2-ethoxy-
ethyl)-1H-pyrazolo [4,3-d]pyrimidines. The alignment of all
the molecules on the template is shown in Fig. 1.
2.2.3. Descriptor calculation
Like many 3D-QSAR methods, a suitable alignment of given
set of molecules was performed using the Vlife MDS 3.5 En-
gine. This was followed by the generation of a common rectan-
gular grid around the molecules. The hydrophobic, steric and
electrostatic interaction energies are computed at the lattice
points of the grid using a methyl probe of charge +1. These
interaction energy values are considered for relationship gener-
ation and utilized as descriptors to decide the nearness between
Figure 1 The alignment of molecules.
3D QSAR, pharmacophore indentiﬁcation studies 269molecules. The term descriptor is utilized in the following dis-
cussion to indicate the ﬁeld values at the lattice points.
2.3. 3D-QSAR studies using multiple linear regressions
Stepwise multiple regression (SMR) is a systematic approach
for selecting useful variable and generating models. Stepwise
forward–backward method from Vlife MDS was used as a var-Table 2 The selected MLR QSAR equations along with statistical
Model no. QSAR model
A pIC50 = 0.0051–0.1171(±0.0107)E_950 7.8993
(±0.7621) S_304 0.2045(±0.0325)E_1021 +0.0277
(±0.0081)E_941 +0.0876(±0.0290)S_1051
Figure 2 Field point foriable selection method, with a cross correlation limit of 0.7 to
eliminate highly inter-correlated variables and a variance cut-
off of 0.5 to eliminate insigniﬁcant variables.
2.4. 3D-QSAR studies using kNN-MFA
The calculated ﬁelds of randomly selected 28 molecules used in
the training set were considered as observations to generate the
QSAR model using a stepwise variable selection (SW) kNN-
MFA method. Plot of the kNN-MFA which shows the relative
position and ranges of the corresponding important electro-
static/steric ﬁelds in the model provides the following guide-
lines for the design of new molecules.
2.4.1. kNN-MFA with stepwise variable selection method
This method employs the kNN classiﬁcation principle com-
bined with the stepwise variable selection procedure for the
optimization of:
(i) The number of nearest neighbors (k) used to estimate
the activity of each compound
(ii) Selection of variables from the original pool of all
molecular descriptors (steric and electrostatic ﬁeld at
the lattice points) that are used to calculate the similar-
ities between compounds (i.e., distances in near-dimen-
sional descriptor space).
Further, a step-by-step search procedure that begins by
developing a hypothetical pharmacophore (HP model) with a
single independent variable and adds independent variablesparameters employed for model selection.
N r2 q2 F value Pred r2
33 0.93 0.89 54.1315 0.8131
3D-QSAR model A.
Figure 3 Correlation plot for 3D-QSAR model A.
270 P. Choudhari, M. Bhatiaone step at a time, examining the ﬁt of the model at each step
(using weighted k-nearest neighbor cross validation procedure)
until there are no more signiﬁcant variables remaining outside
the model is included.Figure 4 Contributio
Figure 5 Field point for2.5. Pharmacophore modeling
Pharmacophore modeling was carried out using the MolSign
module of Vlife MDS 3.5 software. Series of phosphodiester-
ase V inhibitors were ﬁrst aligned on the active molecule. A
pharmacophore model is a set of three-dimensional features
that are necessary for bioactive ligands. Thus, it makes logical
sense to align molecules based on the features that are respon-
sible for bioactivity. The software was set to generate mini-
mum four pharmacophoric features obtained keeping the
tolerance limit at 10 A˚. The maximum distance of 10 A˚ was
kept between two features in pharmacophore identiﬁcation
studies. The average RMSD of the pharmacophore alignments
of each two molecules is 0.055.
3. Results
In the present study, 28 molecules were used in the training set
(Table 1) to derive kNN-MFA 3D-QSAR models with then chart model A.
3D-QSAR model C.
Table 3 The selected kNN-MFA QSAR equations along with statistical parameters employed for model selection.
Model no. Selected descriptors N Descriptor range q2 Pred r2 Degree of freedom
C E_722 33 E_722 0.2429 to 0.1936 0.79 0.72 19
E_653 S_834 30.0000–30.0000
S_834 E_313 0.2465–0.3584
E_313 E_169 0.1678 to 0.0940
E_169
Figure 6 Correlation plot for 3D-QSAR model C.
Table 4 Results of pharmacophore identiﬁcation studies.
Sr. no. Pharmacophoric features Distances
(A˚)
1 Positive ionizable–aromatic 7.806
2 Positive ionizable–hydrogen bond donor 7.094
3 Positive ionizable–hydrogen bond acceptor 5.142
4 Hydrogen bond acceptor–hydrogen bond acceptor 2.341
5 Hydrogen bond acceptor–hydrogen bond donor 2.731
6 Hydrogen bond donor–aromatic 5.091
7 Hydrogen bond acceptor–hydrogen bond donor 3.231
8 Hydrogen bond acceptor–aromatic 6.258
9 Hydrogen acceptor–positive ionisable 2.412
10 Hydrogen acceptor–aromatic 5.971
3D QSAR, pharmacophore indentiﬁcation studies 271number of ﬁeld grid points being not more than seven per
model. To evaluate the predictive ability of generated 3D-
QSAR models, a test set of 5 molecules with regularly distrib-
uted biological activities was used (Table 1). On successful runs
of MLR and kNN-MFA, different sets of equations were gen-
erated and these equations were further analyzed statistically
to select the best model, as shown in Table 2, two models were
selected after screening various combinations of different
descriptors.
4. Discussion
4.1. Interpretation of 3QSAR model (MLR)
The optimum structural requirements of pyrazolo[4,3-d]pyrim-
idines analogs for phosphodiesterase V inhibitors were ob-
tained in the form of the 3D descriptors of model A (Mbarki
et al., 2011). The r2 value for model A was 0.93 (Fig 2). Model
A shows the ﬁrst model which is selected on the basis of statis-
tical coefﬁcients like r2 (0.93) and Pred r2 (0.89). The contrib-
uting descriptors for model A are E_950, S_304, E_1021,
E_941 and S_1051 which are nothing but the electrostatic
and steric interactions at that lattice point. The electrostatic
interaction at the lattice points E_950 and E_1021 is negatively
contributing that means the substitution of electron withdraw-
ing groups on the aromatic ring at r2 can yield potent phospho-
diesterase V inhibitors, also the steric interaction at the lattice
point 304 is also negatively contributing that means the substi-
tution at the R1 should be small, the increase in chain length
could decrease the activity. The electrostatic interaction at
the lattice point 941 and steric interaction at lattice point
1051 are positively contributing so the substitution favoring
this interaction at that lattice point could yield an active mol-
ecule. The correlation plot and contribution plots for model A
are given in Figs. 3 and 4, respectively.4.2. Interpretation of 3QSAR model (kNN-MFA)
4.2.1. Electrostatic ﬁeld
(a) Negative range indicates that negative electrostatic
potential is favorable for increase in the activity and
hence a relatively more electronegative substitution is
preferred in that region.
(b) Positive range indicates that positive electrostatic poten-
tial is favorable for increase in the activity and hence a
relatively less electronegative substitution is preferred
in that region.
4.2.2. Steric ﬁeld
(a) Negative range indicates that negative steric potential is
favorable for increase in the activity and hence a rela-
tively less bulky substituent group is preferred in that
region.
(b) Positive range indicates that positive steric potential is
favorable for increase in the activity and hence a rela-
tively more bulky substituent group is preferred in that
region.
Model C is the secondmodel which is selected on the basis of
statistical coefﬁcients like q2 (0.79) and Pred r2 (0.72). The con-
tributing descriptors for this model are E_722 (0.2429 to
0.1936), S_834 (30.0000–30.0000), E_313 (0.2465–0.3584)
and E_169 (0.1678 to 0.0940). The negative range of the
E_722 (0.2429 to 0.1936) and E_169 (0.1678 to 0.0940)
(Fig 5) indicates that the substitution involving electron deﬁ-
cient group is preferred in that region that is on R2 and R1, also
the positive contribution of S_834 (30.0000–30.0000) indicates
the substitution of bulkier groups with less electron density that
could yield more active molecules. The lattice point at E_313
(0.2465–0.3584) is positively contributing so the substitutions
Figure 7 Pharmacophore features of molecules.
272 P. Choudhari, M. Bhatiawhich are increasing the electron density around these lattice
points could give more potential inhibition. The negative range
at the lattice point E_169 (0.1678 to 0.0940) indicates the
importance of substitution of electron withdrawing groups in
pyrazole ring which can stabilize the ring and also increase
the activity of the molecules (Table 3). The correlation plot
for model C is given in Fig. 6.
4.2.3. Pharmacophore identiﬁcation studies using Vlife MDS 3.5
A set of pharmacophore hypothesis was generated using the
mole sign module of Vlife MDS 3.5 on the reported inhibitors
of phosphodiesterase V. Each hypothesis was found to contain
common features like hydrogen bond donor, hydrogen bond
acceptor, and positive ionizable, aromatic. Results of pharma-
cophore identiﬁcation studies revealed that the hydrogen bond
donor, hydrogen bond acceptor, positive ionizable, aromatic
features are important for the activity. The results of pharma-
cophore identiﬁcation studies are given in Table 4 and Fig. 7.
5. Conclusion
In this work we identiﬁed the structural requirement of 1-(2-
ethoxyethyl)-1H-pyrazolo [4,3-d] pyrimidines for the inhibi-
tion of phosphodiesterase V. The two different QSAR models
are generated by using two different principles, both the
models are showing similar results which indicate that this
kNN-MFA technique can be utilized for cross validation of
the results of multiple linear regression studies.Acknowledgment
The authors are thankful to Dr. H.N. More, Principal Bharati
Vidyapeeth College of Pharmacy, Kolhapur, for providing
facilities to carry out the research work.References
Chang, T.T., Huang, H.J., Lee, K.J., Yu, H.W., Chen, H.Y., Tsai,
F.U., Sun, Mao-Feng, Chen, Calvin Yu-Chian, 2010. Key features
for designing phosphodiesterase-5 inhibitors. J. Biomol. Struct.
Dyn. 28, 309–321.
Chen, G., Wang, H., Robinson, H., Cai, J., Wan, Y., Ke, H., 2008. An
insight into the pharmacophores of phosphodiesterase-5 inhibitors
from synthetic and crystal structural studies. Biochem. Pharm. 75,
1717–1728.
Chen, C., Chang, Y., Bau, D., Huang, H., Tsai, F., Tsai, C., Chen,
C.Y., 2009. Discovery of potent inhibitors for phosphodiesterase 5
by virtual screening and pharmacophore analysis. Acta Pharmacol.
Sin. 30, 1186–1194.
Fegade, J.D., Rane, S.S., Chaudhari, R.Y., Patil, V.R., 2009. 3D-
QSAR study of benzylidene derivatives as selective cyclooxygenase-
2-inhibitors. Digest J. Nanomater. Biostruct. 4, 145–154.
Guazzi, M., 2008. Clinical use of phosphodiesterase-5 inhibitors in
chronic heart failure. Circ. Heart Fail. 1, 272–280.
Jhaa, K.K., Samadc, A., Kumar, Y., Shaharyar, M., Khosad, R.,
Jaina, J., Bansald, S., 2009. 3D QSAR studies of 1,3,4-oxadiazole
derivatives as antimycobacterial agents. IJPR 8, 163–167.
Matsumoto, T., Kobayashi, T., Kamata, K., 2003. Phosphodiesterases
in the vascular system. J. Smooth Muscle Res. 39, 67–86.
Mbarki, S., Dguigui, K., Hallaoui, M.E., 2011. Construction of 3D-
QSAR models to predict antiamoebic activities of pyrazoline and
dioxazoles derivatives. J. Mater. Environ. Sci. 2, 61–70.
McAllister-Lucas, L.M., Sonnenburg, W.K., Kadlecek, A., Seger, D.,
Trong, H.L., Colbran, J.L., Thomas, M.K., Walsh, K.A., Francis,
S.H., Corbin, J.D., Beavo, J.A., 1993. The structure of a bovine
lung cGMP-binding, cGMP-speciﬁc phosphodiesterase deduced
from a cDNA clone. J. Biol. Chem. 268, 22863–22873.
Palmer, M.J., Bell, A.S., Fox, D.N.A., Brown, D.G., 2007. Design of
second generation phosphodiesterase 5 inhibitors. Curr. Top. Med.
Chem. 7, 405–419.
Reffelmann, T., Kloner, R.A., 2009. Phosphodiesterase 5 inhibitors:
are they cardioprotective. Cardiovasc. Res. 83, 204–212.
Rotella, D.P., 2002. Phosphodiesterase 5 inhibitors: current status and
potential applications. Drug Discov. 1 (2002), 674–682.
3D QSAR, pharmacophore indentiﬁcation studies 273Sausbier, M., Schubert, R., Voigt, V., Hirneiss, C., Pfeifer, A., Korth,
M., Kleppisch, T., Ruth, P., Hofmann, F., 2000. Mechanisms of
NO/cGMP-dependent vasorelaxation. Circ. Res. 87, 825–830.
Sharma, M.C., Sharma, S., 2010. 3D-quantitative structure–activity
relationship analysis of some 2-substituted halogenbenzimidazoles
analogues with antimycobacterial activity. Int. J. ChemTech. Res.
2, 606–614.
Srivani, P., Srinivas, E., Raghu, R., Narahari Sastry, G., 2007.
Molecular modeling studies of pyridopurinone derivatives potential
phosphodiesterase 5 inhibitors. J. Mol. Graph. Model. 26, 378–390.Tollefson, M.B., Acker, B.A., Jacobsen, E.J., Hughes, R.O., Walker,
J.K., Fox, D.N.A., Palmer, M.J., Freeman, S.K., Yu, Y., Bond,
B.R., 2010. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as
potent phosphodiesterase 5 (PDE5) inhibitors. Bioorg. Med. Chem.
Lett. 20, 3120–3124.
Yang, G.F., Lu, H.T., Xiong, Y., Zhan, C.G., 2006. Understanding
the structure–activity and structure–selectivity correlation of cyclic
guanine derivatives as phosphodiesterase-5 inhibitors by molecular
docking, CoMFA and CoMSIA analyses. Bioorg. Med. Chem. 14,
1462–1473.
